Should Global Pharmas Focus More On Korean Partners?

Early-Stage, Innovative Assets May Stand Out

 
• By Jung Won Shin

PharmaVentures’ Adrian Dawkes talks about how COVID-19 will impact pharma deals going forward and how Korean firms in particular may be able to grab opportunities in the global arena. 

post COVID-19
Deals May Slow On COVID-19-Related Trial Delays But Korea May Benefit • Source: Alamy

More from South Korea

More from Focus On Asia